Becton, Dickinson and Company $BDX Shares Bought by Brandes Investment Partners LP

Brandes Investment Partners LP raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,229,707 shares of the medical instruments supplier’s stock after buying an additional 77,104 shares during the quarter. Becton, Dickinson and Company makes up 1.8% of Brandes Investment Partners LP’s investment portfolio, making the stock its 12th largest position. Brandes Investment Partners LP’s holdings in Becton, Dickinson and Company were worth $238,651,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC raised its stake in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the last quarter. United Bank raised its stake in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after buying an additional 993 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after buying an additional 6,058 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.4%

Becton, Dickinson and Company stock opened at $152.05 on Wednesday. The stock has a market cap of $41.90 billion, a PE ratio of 38.49, a P/E/G ratio of 10.62 and a beta of 0.22. The stock has a 50-day moving average price of $150.53 and a 200 day moving average price of $174.85. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Analysts Set New Price Targets

BDX has been the subject of several research reports. Piper Sandler cut their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Barclays lifted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Stifel Nicolaus cut their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Finally, Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $183.64.

Insider Buying and Selling

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 2,913 shares of company stock worth $426,806. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.